Amgen's Dazodalibep Clears Key Sjögren's Hurdle, Setting Up Race With Novartis

Amgen has cleared a meaningful hurdle in Sjögren's disease. The company said Tuesday its drug dazodalibep met the primary and key secondary goals of a pivotal Phase 3 trial, with results characterized as both statistically significant and clinically meaningful. That matters because Sjögren's, which affects up to 4 million Americans according to the Sjögren's Foundation, has no FDA-approved treatment. It is the second most common rheumatic autoimmune condition in the country.

Amgen has not released the actual numbers. Specific figures are being saved for a future medical meeting. That decision is standard practice in pharma, but it leaves investors and clinicians working from a headline claim rather than hard data, which matters given how this disease has historically resisted drug development.

Sjögren's is a systemic autoimmune disease, but its most visible damage lands on the tear ducts and salivary glands, leaving patients with chronic dry eyes and dry mouth. The trial measured change on a disease activity scale at week 48, with secondary endpoints covering dryness, joint symptoms, and fatigue. Amgen said improvement showed up as early as week 4 and held through the full 48 weeks. Adverse events, described as generally mild to moderate, included nasopharyngitis, urinary tract infection, hypertension, and infusion-related reactions.

Dr. Ghaith Noaiseh, the trial's lead investigator and associate professor of medicine at the University of Kansas Medical Center's division of allergy, clinical immunology and rheumatology, called the results support for dazodalibep as "an emerging treatment for improving systemic disease activity" and "an important advance for the field." That is investigator language, not regulatory language, but it signals confidence from the clinical side.

The Competitive Landscape

Dazodalibep works by blocking CD40 ligand, a protein involved in immune signaling. As a fusion protein, it disrupts the interaction between CD40L and immune cells, aiming to dial down the autoimmune activity that drives Sjögren's.

Novartis is pursuing a different mechanism, and it has a head start. Its antibody drug ianalumab targets B cells through a dual approach: depleting them directly while also blocking their activation by binding to the BAFF receptor. Novartis presented results from two Phase 3 studies at the American College of Rheumatology Convergence congress last fall, showing statistically significant and clinically meaningful improvement at 48 weeks. Ianalumab is already under FDA review, with a decision expected in coming months.

That timing gap is the real story here. Novartis could be first to market in a disease with zero approved options, giving it a durable commercial edge even if Amgen's data eventually proves comparable or stronger. Amgen's decision to withhold specifics until a medical meeting makes it harder, for now, to judge whether dazodalibep offers a meaningfully different efficacy or safety profile than ianalumab.

Amgen is running a second Phase 3 study targeting a different patient population: those with high symptom burden but low systemic disease activity. That study is expected to wrap up in the fourth quarter. William Blair analyst Matt Phipps flagged this segmentation approach as strategically significant beyond just Amgen's own program. "More broadly for [Sjögren's] drug development, the positive readout also potentially adds support for Amgen's novel patient segmentation strategy into separate systemic disease and symptomatic disease buckets," Phipps wrote in a note to investors.

Phipps also said he expects the FDA will require two positive Phase 3 studies before approving dazodalibep in Sjögren's, meaning this single readout, however encouraging, is not the finish line. He described the drug as relatively high risk. That assessment reflects the disease itself: Sjögren's has a long history of frustrating drug developers because of high placebo response rates and wide variation in how the disease presents across patients. Trials in this space have failed before for reasons that had little to do with drug mechanism and everything to do with trial design and patient heterogeneity.

There is a silver lining in the readthrough. Phipps noted the first Phase 3 study could offer some positive signal for the second, ongoing trial, though he was careful to point out the two studies enrolled distinct patient populations. That caveat matters. A drug that works well in moderate-to-severe systemic disease does not automatically translate to success in a population defined by high symptom burden but lower systemic activity. These are different biological pictures, and regulators will likely evaluate them as such.

The Bottom Line

Amgen has real, if incomplete, good news. A statistically significant and clinically meaningful topline result in a disease with no approved therapy is not a small thing, and it adds a second viable mechanism, CD40L blockade, to a field so far dominated by B-cell approaches. The University of Kansas investigator's endorsement adds clinical credibility, and the durability of response through 48 weeks is a reasonable sign for real-world utility.

But the risk calculus has not shifted dramatically. Novartis is ahead in the regulatory queue, with an FDA decision on ianalumab expected within months. Amgen still needs a second successful Phase 3 study by Phipps' estimate, and the specific numbers that would let analysts and physicians compare dazodalibep against ianalumab head to head remain unpublished. Sjögren's remains a graveyard for otherwise promising compounds, largely due to placebo response and patient variability, not mechanism failure.

Investors should treat this as a positive data point in a multi-year approval process, not a de-risking event. The read-through to Amgen's second Phase 3 trial, due to complete in the fourth quarter, will matter more than this initial headline. Until full data appears at a medical meeting and the second trial reads out, dazodalibep is a promising candidate in a hard therapeutic area, competing against a rival with a regulatory head start.